AGN.c invited to present at the American Cough Conference Algernon Pharmaceuticals Inc. (AGN.c AGNPF) is trading in the green on the CSE after announcing today that it has been invited to present the results from its Phase 2a Study of its Ifenprodil drug at the 9th American Cough Conference.
The study look at how Ifenprodil could help treat idiopathic pulmonary fibrosis (IPF) & chronic cough and had multiple positive results.
The American Cough Conference is held every 2 years and is the leading educational meeting for those involved in the research and management of patients with coughing issues.
Their 9th conference will take place in June of next year.
Conference Chair Dr. Peter Dicpinigaitis says that, if successful, he expects Ifenprodil will be a first-in-class treatment for chronic cough & IPF.
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-invited-present-phase-110700114.html